Nivolumab is a fully human immunoglobulin G4 immune checkpoint inhibitor antibody approved for use in the treatment of several malignancies. Severe side effects such as Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) have only extremely rarely been reported with this drug. We present herein a patient who developed SJS after 16 weeks of therapy with nivolumab. A week prior to this event, he developed a pruriginous papulo-erythematous rash. Prompt recognition of this phenomenon, immune checkpoint inhibitor discontinuation and steroid therapy are necessary steps in order to avoid dismal outcomes.
Get full access to this article
View all access options for this article.
References
1.
GuoLZhangHChenB. Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer2017; 8: 410–416.
2.
TopalianSLSznolMMcDermottDF, et al.Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol2014; 32: 1020–1030.
3.
GettingerSNHornLGandhiL, et al.Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol2015; 33: 2004–2012.
4.
GoldinerSSteigerPMeierB, et al.Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res2016; 22: 4023–4029.
5.
FakoyaAOmenyiPAnthonyP, et al.Stevens–Johnson syndrome and toxic epidermal necrolysis: extensive review of reports of drug-induced etiologies, and possible therapeutic modalities. Open Access Maced J Med Sci2018; 6: 730–738.
6.
SalatiMPifferiMBaldessariC, et al.Stevens–Johnson syndrome during nivolumab treatment of NSCLC. Ann Oncol2018; 29: 283–284.
7.
BuchbinderEDesaiA. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol2016; 39: 89–106.
KumarRDasADasS. Management of Stevens–Johnson syndrome-toxic epidermal necrolysis: looking beyond guidelines. Indian J Dermatol2018; 63: 117–124.
10.
ThebeauMRubinKHofmannM, et al.Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma: a nursing perspective. J Am Assoc Nurse Pract2017; 29: 294–303.
11.
Hwang A, Iskandar A and Dasanu CA. Stevens–Johnson syndrome manifesting late in the course of pembrolizumab therapy. J Oncol Pharm Pract 2018 Aug 7:1078155218791314. doi: 10.1177/1078155218791314. [Epub ahead of print].
